<DOC>
	<DOCNO>NCT01724450</DOCNO>
	<brief_summary>The purpose study evaluate carvedilol prevent cardiotoxicity chemotherapy breast cancer .</brief_summary>
	<brief_title>Carvedilol Effect Preventing Chemotherapy - Induced Cardiotoxicity</brief_title>
	<detailed_description>Dilated cardiomyopathy secondary chemotherapy account approximately 1 % dilated cardiomyopathy . Initial study show beneficial effect use carvedilol prevention chemotherapy-induced cardiomyopathy . This study objective evaluate effectiveness carvedilol prevention chemotherapy-induced cardiomyopathy . Will select 200 patient refer chemotherapy include anthracyclines breast cancer.These patient randomize carvedilol placebo periodic assessment cardiac function echocardiography biomarkers complete chemotherapy 24 month later .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Patients diagnose breast cancer , indication chemotherapy include anthracycline . Failure analysis ventricular function ; History chemotherapy radiotherapy ; Previous symptom heart failure ; Presence cardiomyopathy ; Presence Coronary Artery Disease ; Aortic valve disease moderate severe mitral regurgitation ; Contraindication use βblocker ; Use inhibitor angiotensin convert enzyme , angiotensin receptor blocker βblockers . Patients HER 2 expression</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Cardiotoxicity</keyword>
	<keyword>Biomarkers</keyword>
</DOC>